<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>DFSP-2</td>
<td>Based on panel discussion, the consensus was to clarify the systemic therapy options for the treatment of patients with metastatic disease with the following footnote: “AIM (doxorubicin/ifosfamide/mesna) regimen or single-agent therapy with doxorubicin, ifosfamide, epirubicin, gemcitabine, dacarbazine, liposomal doxorubicin, temozolomide, vinorelbine, or pazopanib may be considered.”</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>